BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Jan. 5, 2006
View Archived Issues
After Adding $25M, Novacea To Launch DN-101 Phase III
Closing the second tranche of a Series C financing begun two years ago, Novacea Inc. raised more than $25 million - money it will use to launch a Phase III trial with DN-101 to treat advanced prostate cancer. (BioWorld Today)
Read More
Alcon Signs Kalypsys For Small-Molecule Research
Read More
Defense Bill Provides Funding For Research By AVI, Others
Read More
Medicure Raising C$12M In Bought Deal Financing
Read More
Other News To Note
Read More
Appointments And Advancements
Read More